NCT04071756: Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have a plan to initiate a weekly regorafenib treatment – see trial for details

Comments are closed.

Up ↑